Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients-Reference-Cited by-同舟云学术

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients

Published:2019-07 Issue:4 Volume:20 Page:237-247.e1
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Cortellini Alessio^ORCID,Chiari Rita,Ricciuti Biagio^ORCID,Metro Giulio^ORCID,Perrone Fabiana,Tiseo Marcello,Bersanelli Melissa,Bordi Paola,Santini Daniele,Giusti Raffaele^ORCID,Grassadonia Antonino,Di Marino Pietro,Tinari Nicola,De Tursi Michele,Zoratto Federica,Veltri Enzo,Malorgio Francesco,Garufi Carlo,Russano Marco,Anesi Cecilia,Zeppola Tea,Filetti Marco^ORCID,Marchetti Paolo,Berardi Rossana,Rinaldi Silvia,Tudini Marianna,Silva Rosa Rita,Pireddu Annagrazia,Atzori Francesco,Iacono Daniela,Migliorino Maria Rita,Porzio Giampiero,Cannita Katia,Ficorella Corrado,Buti Sebastiano^ORCID

Funder

Consorzio Interuniversitario Nazionale per la Bio-Oncologia

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference27 articles.

1. Not all immune-checkpoint inhibitors are created equal: meta-analysis and systematic review of immune-related adverse events in cancer trials;El Osta;Crit Rev Oncol Hematol,2017

2. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature;Pillai;Cancer,2018

3. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper;Champiat;Ann Oncol,2016

Cited by 131 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC;Immunotherapy;2024-09-13

2. Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness;Frontiers in Oncology;2024-06-26

3. The Potential Adverse Impact of Post-Treatment Thrombocytopenia on Clinical Outcomes in Cancer Patients Treated With Immune Checkpoint Inhibitors;Cureus;2024-06-11

5. Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias;Lung Cancer;2024-06